Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients.
H. Tedesco Silva,Diane M. Cibrik,Thomas D. Johnston,E. Lackova,K. Mange,C. Panis,Rowan G. Walker,Z. Wang,Gazi B. Zibari,Yu Seun Kim +9 more
TLDR
The use of everolimus with progressive reduction in CsA exposure, up to 60% at 1 year, resulted in similar efficacy and renal function compared with standard‐exposure Cs a plus MPA.About:
This article is published in American Journal of Transplantation.The article was published on 2010-06-01 and is currently open access. It has received 252 citations till now. The article focuses on the topics: Everolimus.read more
Citations
More filters
Journal ArticleDOI
Strategies for the management of adverse events associated with mTOR inhibitors
TL;DR: Mammalian target of rapamycin (mTOR) inhibitors are used as potent immunosuppressive agents in solid-organ transplant recipients and as antineoplastic therapies for various cancers and most AEs can be effectively detected and managed or reversed with careful monitoring and appropriate interventions.
Journal ArticleDOI
Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial.
Howard J. Eisen,Jon A. Kobashigawa,Randall C. Starling,Daniel F. Pauly,Abdallah G. Kfoury,Heather J. Ross,Shoei-Shen Wang,Bernard Cantin,A. Van Bakel,Greg Ewald,Stephan Hirt,Hans B. Lehmkuhl,Anne Keogh,Mauro Rinaldi,Luciano Potena,Andreas Zuckermann,Gaohong Dong,C. Cornu-Artis,Patricia Lopez +18 more
TL;DR: Everolimus 1.5 mg with reduced‐dose cyclosporine offers similar efficacy to MMF with standard‐doseCyprusporine and reduces intimal proliferation at 12 months in de novo heart transplant recipients.
Journal ArticleDOI
Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation
Julio Pascual,Stefan P Berger,Oliver Witzke,H. Tedesco,Shamkant Mulgaonkar,Y. Qazi,Steven J. Chadban,Federico Oppenheimer,Claudia Sommerer,Rainer Oberbauer,Yoshihiko Watarai,Christophe Legendre,Franco Citterio,Mitchell L. Henry,Titte R. Srinivas,Wen-Lin Luo,AnaMaria Marti,Peter Bernhardt,Flavio Vincenti +18 more
TL;DR: In kidney transplant recipients at mild-to-moderate immunologic risk, everolimus was noninferior to MPA for a binary composite end point assessing immunosuppressive efficacy and preservation of graft function.
Journal ArticleDOI
Renal Function at Two Years in Liver Transplant Patients Receiving Everolimus: Results of a Randomized, Multicenter Study
Faouzi Saliba,P De Simone,Frederik Nevens,L. De Carlis,H.J. Metselaar,Susanne Beckebaum,Sven Jonas,Debra L. Sudan,L Fischer,Christophe Duvoux,Kenneth D. Chavin,Baburao Koneru,M. A Huang,William C. Chapman,D Foltys,Gaohong Dong,Patricia Lopez,John J. Fung,Guido Junge +18 more
TL;DR: Early introduction of everolimus with reduced‐exposure tacrolimus at 1 month after liver transplantation provided a significant and clinically relevant benefit for renal function at 2 years posttransplant.
Journal ArticleDOI
Conversion of Long-Term Kidney Transplant Recipients From Calcineurin Inhibitor Therapy to Everolimus : A Randomized, Multicenter, 24-Month Study
Hallvard Holdaas,Lionel Rostaing,Daniel Serón,Edward Cole,Jeremy R. Chapman,Bengt Fellström,Erik H. Strøm,Alan G. Jardine,Karsten Midtvedt,Uwe Machein,Bettina Ulbricht,Alexander Karpov,Philip J. O'Connell +12 more
TL;DR: Conversion to everolimus with CNI elimination or minimization a mean of 5.6 years after kidney transplantation had no overall renal benefit and was associated with more frequent adverse events and discontinuations.
References
More filters
Journal ArticleDOI
A sharper Bonferroni procedure for multiple tests of significance
TL;DR: In this article, a simple procedure for multiple tests of significance based on individual p-values is derived, which is sharper than Holm's (1979) sequentially rejective procedure.
Journal ArticleDOI
Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third national health and nutrition examination survey
TL;DR: CKD is common and warrants improved detection and classification using standardized criteria to improve outcomes, and CCr estimates showed a steeper decline with age and were lower in non-Hispanic blacks.
Journal ArticleDOI
Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection.
Lorraine C. Racusen,Robert B. Colvin,Kim Solez,Michael J. Mihatsch,Philip F. Halloran,Patricia Campbell,Michael Cecka,Jean Pierre Cosyns,Anthony J. Demetris,Michael C. Fishbein,Agnes B. Fogo,Peter N. Furness,Ian W. Gibson,Denis Glotz,Pekka Häyry,Lawrence Hunsickern,Michael Kashgarian,Ronald H. Kerman,Alex J. Magil,Robert A. Montgomery,Kunio Morozumi,Volker Nickeleit,Parmjeet Randhawa,Heinz Regele,Daniel Serón,Surya V. Seshan,Stale Sund,Kiril Trpkov +27 more
TL;DR: This article presents international consensus criteria for and classification of AbAR developed based on discussions held at the Sixth Banff Conference on Allograft Pathology in 2001, to be revisited as additional data accumulate in this important area of renal transplantation.
Journal ArticleDOI
Post-transplant renal function in the first year predicts long-term kidney transplant survival
Sundaram Hariharan,Maureen A. McBride,Wida S. Cherikh,Christine B. Tolleris,Barbara A. Bresnahan,Christopher P. Johnson +5 more
TL;DR: Recent improvements in graft half-life are related to conservation of renal function within the first year post-transplantation, and one-year creatinine and Delta Creatinine values predict long-term renal graft survival.
Journal ArticleDOI
SDZ RAD, A NEW RAPAMYCIN DERIVATIVE: Pharmacological Properties In Vitro and In Vivo
Walter Schuler,Richard Sedrani,Sylvain Cottens,B Häberlin,M Schulz,Henk-Jan Schuurman,Gerhard Zenke,Hans-Guenter Zerwes,Max H. Schreier +8 more
TL;DR: SDZ RAD is a new, orally active rapamycin-derivative that is immunosuppressive in vitro that efficiently prevents graft rejection in rat models of allotransplantation and has been selected for development for use in combination with cyclosporine A to prevent acute and chronic rejection after solid organ allotransplplantation.
Related Papers (5)
Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies.
Stefan Vitko,H. Tedesco,Josette Eris,Julio Pascual,J. Whelchel,John C. Magee,Scott B. Campbell,Giovanni Civati,Bernard Bourbigot,Gentil Alves Filho,John Leone,Valter Duro Garcia,Paolo Rigotti,Ronaldo de Matos Esmeraldo,Vincenzo Cambi,Tomas Haas,Annette Jappe,Peter Bernhardt,Johanna Geissler,Nathalie Cretin +19 more